About 200 people sign up for Nanocovax vaccine trial
VOV.VN - As many as 200 people have registered to participate in clinical trials for the locally-produced Nanocovax vaccine, with screening underway to select 60 people aged between 18 and 50 for the first phase, said Nguyen Ngo Quang, deputy director of the Department of Science, Technology and Training under the Ministry of Health on December 16.
According to Quang, the volunteers who will take part in the trials will be eligible to purchase health insurance in line with regulations, with this being done by the vaccine manufacturer.
This comes after Ho Nhan, general director of Nanogen Company, shared with reporters on December 10 at the launching ceremony to mark the start of the Nanocovax vaccine human testing programme, that the firm had purchased a VND20 billion risk insurance package for volunteers. As such, all those participating in trials for the vaccine will be bought health insurance in order to prevent risks.
Nanocovax will be the first COVID-19 vaccine produced by the country and is currently in the process of undergoing clinical trials on humans. The product has been jointly developed by two research units, Nanogen company along with the Military Medical Academy.
All participants in trials will receive two doses of the vaccine via intramuscular infection or placebo, during phases two and three, with there being a pause between doses of 28 days. The duration for each volunteer will be approximately 56 days to assess the study goal and follow up until the sixth month on from the first injection.
Ho Nhan said that providing the testing process goes smoothly, the vaccine is expected to be launched in May next year.